Systematic Review and Meta-Analysis of Damage Associated Molecular Patterns HMGB1 and S100B in Schizophrenia

다국어 초록 (Multilingual Abstract)

Objective Immune system dysregulation is hypothesised to be central to the aetiopathogenesis of schizophrenia; however, the role of sterile inflammation remains unclear. Damage associated molecular patterns are key initiators of sterile inflammation and are detectable in peripheral blood.
Methods A defined systematic search of the Web of Science, PubMed, and Scopus was performed to identify adult case-control studies published between January 1990 and June 2022. Three studies consisting of 242 cases and 83 controls met inclusion for the systematic review and meta-analysis of HMGB1 while twenty-eight studies consisting of 1,544 cases and 1,248 healthy controls were included for S100B.
Results A significant standardised mean difference in peripheral S100B and HMGB1 concentrations was detected between cases and controls. S100B subgroup analysis determined the largest significant effect size for unmedicated individuals diagnosed with schizophrenia.
Conclusion This study provides evidence that peripheral S100B and HMGB1 concentrations are elevated in individuals diagnosed with schizophrenia when compared with healthy controls. These results should be interpreted with caution as significant heterogeneity was present during meta-analysis of S100B in the entire sample and in sub-group analysis. The persistence of significant heterogeneity throughout subgroup analysis indicates that the current diagnostic groupings may be a barrier to understanding human behaviours and emotions.

참고문헌 (Reference)

1 Song XQ, "The interaction of nuclear factor-kappa B and cytokines is associated with schizophrenia" 65 : 481-488, 2009

2 Cochran WG, "The combination of estimates from different experiments" 10 : 101-129, 1954

3 Engel GL, "The clinical application of the biopsychosocial model" 6 : 101-124, 1981

4 Oris C, "The biomarker S100B and mild traumatic brain injury: a meta-analysis" 141 : e20180037-, 2018

5 Cuthbert BN, "The RDoC framework: facilitating transition from ICD/DSM to dimensional approaches that integrate neuroscience and psychopathology" 13 : 28-35, 2014

6 Page MJ, "The PRISMA 2020 statement: an updated guideline for reporting systematic reviews" 372 : n71-, 2021

7 Overall JE, "The Brief Psychiatric Rating Scale (BPRS):recent developments in ascertainment and scaling" 24 : 97-99, 1988

8 Aleksovska K, "Systematic review and meta-analysis of circulating S100B blood levels in schizophrenia" 9 : e106342-, 2014

9 Gógl G, "Structural basis of ribosomal S6 kinase 1 (RSK1) inhibition by S100B protein:modulation of the extracellular signal-regulated kinase (ERK) signaling cascade in a calcium-dependent way" 291 : 11-27, 2016

10 Hedges LV, "Statistical methods for meta-analysis" Academic Press 1985

11 Tzoulaki I, "Size at birth, weight gain over the life course, and lowgrade inflammation in young adulthood: northern Finland 1966 Birth Cohort study" 29 : 1049-1056, 2008

12 Milleit B, "Serum S100B protein is specifically related to white matter changes in schizophrenia" 10 : 33-, 2016

13 Schroeter ML, "Serum S100B is increased during early treatment with antipsychotics and in deficit schizophrenia" 62 : 231-236, 2003

14 McCutcheon RA, "Schizophrenia-an overview" 77 : 201-210, 2020

15 O’Connell G, "Schizophrenia risk genes: implications for future drug development and discovery" 81 : 1367-1373, 2011

16 Andreasen NC, "Scale for the assessment of positive symptoms (SAPS)"

17 Li D, "S100B suppresses the differentiation of C3H/10T1/2 murine embryonic mesenchymal cells into osteoblasts" 14 : 3878-3886, 2016

18 Steiner J, "S100B serum levels in schizophrenia are presumably related to visceral obesity and insulin resistance" 2010 : 480707-, 2010

19 Rothermundt M, "S100B serum levels and long-term improvement of negative symptoms in patients with schizophrenia" 29 : 1004-1011, 2004

20 Bianchi R, "S100B protein stimulates microglia migration via RAGE-dependent up-regulation of chemokine expression and release" 286 : 7214-7226, 2011

21 Riuzzi F, "S100B protein regulates myoblast proliferation and differentiation by activating FGFR1 in a bFGF-dependent manner" 124 (124): 2389-2400, 2011

22 Businaro R, "S100B protects LAN-5 neuroblastoma cells against Abeta amyloid-induced neurotoxicity via RAGE engagement at low doses but increases Abeta amyloid neurotoxicity at high doses" 83 : 897-906, 2006

23 Rothermundt M, "S100B in brain damage and neurodegeneration" 60 : 614-632, 2003

24 Rickmann M, "S100 protein expression in subpopulations of neurons of rat brain" 67 : 977-991, 1995

25 Cochran AJ, "S-100 protein remains a practical marker for melanocytic and other tumours" 3 : 325-330, 1993

26 Laird NM, "Random-effects models for longitudinal data" 38 : 963-974, 1982

27 Cannon TD, "Progressive reduction in cortical thickness as psychosis develops: a multisite longitudinal neuroimaging study of youth at elevated clinical risk" 77 : 147-157, 2015

28 Moher D, "Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement" 339 : b2535-, 2009

29 Ling SH, "Plasma S-100B protein in Chinese patients with schizophrenia: comparison with healthy controls and effect of antipsychotics treatment" 41 : 36-42, 2007

30 Sarandol A, "Oxidative-antioxidative systems and their relation with serum S100 B levels in patients with schizophrenia : effects of short term antipsychotic treatment" 31 : 1164-1169, 2007

31 Begg CB, "Operating characteristics of a rank correlation test for publication bias" 50 : 1088-1101, 1994

32 Youn JH, "Nucleocytoplasmic shuttling of HMGB1 is regulated by phosphorylation that redirects it toward secretion" 177 : 7889-7897, 2006

33 Schroeter ML, "Neuron-specific enolase is unaltered whereas S100B is elevated in serum of patients with schizophrenia--original research and meta-analysis" 167 : 66-72, 2009

34 Hendouei N, "Negative correlation between serum S100B and leptin levels in schizophrenic patients during treatment with clozapine and risperidone: preliminary evidence" 15 : 323-330, 2016

35 Bonaldi T, "Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion" 22 : 5551-5560, 2003

36 Weinhard L, "Microglia remodel synapses by presynaptic trogocytosis and spine head filopodia induction" 9 : 1228-, 2018

37 Miller BJ, "Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects" 70 : 663-671, 2011

38 Cuijpers P, "Meta-analyses in mental health research. A practical guide"

39 Higgins JP, "Measuring inconsistency in meta-analyses" 327 : 557-560, 2003

40 O’Connell K, "Levels of S100B are raised in female patients with schizophrenia" 13 : 146-, 2013

41 Romeo B, "Kinetics of cytokine levels during antipsychotic treatment in schizophrenia: a meta-analysis" 21 : 828-836, 2018

42 Şahin M, "Jamovi: an easy to use statistical software for the social scientists" 6 : 670-692, 2019

43 Khandaker GM, "Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment" 2 : 258-270, 2015

44 Lara DR, "Increased serum S100B protein in schizophrenia : a study in medication-free patients" 35 : 11-14, 2001

45 Kim HR, "Increased serum S100B protein in chronic schizophrenic patients in Korea" 45 : 1561-1563, 2007

46 Qi LY, "Increased serum S100B levels in chronic schizophrenic patients on long-term clozapine or typical antipsychotics" 462 : 113-117, 2009

47 Zhang XY, "Increased serum S100B in never-medicated and medicated schizophrenic patients" 44 : 1236-1240, 2010

48 Schmitt A, "Increased serum S100B in elderly, chronic schizophrenic patients : negative correlation with deficit symptoms" 80 : 305-313, 2005

49 Uzbay T, "Increased plasma agmatine levels in patients with schizophrenia" 47 : 1054-1060, 2013

50 Steiner J, "Increased cerebrospinal fluid and serum levels of S100B in first-onset schizophrenia are not related to a degenerative release of glial fibrillar acidic protein, myelin basic protein and neurone-specific enolase from glia or neurones" 77 : 1284-1287, 2006

51 Šakić M, "Increased calcium-independent lipoprotein phospholipase A2 but not protein S100 in patients with schizophrenia" 28 : 45-50, 2016

52 Rothermundt M, "Increased S100B blood levels in unmedicated and treated schizophrenic patients are correlated with negative symptomatology" 6 : 445-449, 2001

53 Michetti F, "Immunohistochemical localization of S-100-containing cells in non-nervous structures of the human eye" 10 : 765-773, 1986

54 van Kesteren CF, "Immune involvement in the pathogenesis of schizophrenia:a meta-analysis on postmortem brain studies" 7 : e1075-, 2017

55 World Health Organization, "ICD-10: international statistical classification of diseases and related health problems: 10th revision (2nd ed)"

56 Hong W, "Higher plasma S100B concentrations in schizophrenia patients, and dependently associated with inflammatory markers" 6 : 27584-, 2016

57 Yilmaz N, "High mobility group box-1 levels in schizophrenia: potential biomarker of remission phase" 40 : 295-301, 2021

58 Allsopp K, "Heterogeneity in psychiatric diagnostic classification" 279 : 15-22, 2019

59 Steiner J, "Haloperidol and clozapine decrease S100B release from glial cells" 167 : 1025-1031, 2010

60 Yang M, "HMGB1-induced endothelial cell pyroptosis is involved in systemic inflammatory response syndrome following radiofrequency ablation of hepatic hemangiomas" 11 : 7555-7567, 2019

61 Brezniceanu ML, "HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma" 17 : 1295-1297, 2003

62 Kang R, "HMGB1 in health and disease" 40 : 1-116, 2014

63 Sha Y, "HMGB1 develops enhanced proinflammatory activity by binding to cytokines" 180 : 2531-2537, 2008

64 Murray CJ, "Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study" 349 : 1436-1442, 1997

65 Rothermundt M, "Glial cell dysfunction in schizophrenia indicated by increased S100B in the CSF" 9 : 897-899, 2004

66 Rothermundt M, "Glial cell activation in a subgroup of patients with schizophrenia indicated by increased S100B serum concentrations and elevated myo-inositol" 31 : 361-364, 2007

67 Dennison CA, "Genome-wide association studies in schizophrenia: recent advances, challenges and future perspective" 217 : 4-12, 2020

68 Andersson U, "Extracellular HMGB1 as a therapeutic target in inflammatory diseases" 22 : 263-277, 2018

69 Starkie R, "Exercise and IL-6 infusion inhibit endotoxin-induced TNF-alpha production in humans" 17 : 884-886, 2003

70 Xiong Z, "Enhanced calcium transients in glial cells in neonatal cerebellar cultures derived from S100B null mice" 257 : 281-289, 2000

71 Wiesmann M, "Elevated plasma levels of S-100b protein in schizophrenic patients" 45 : 1508-1511, 1999

72 Canetta S, "Elevated maternal C-reactive protein and increased risk of schizophrenia in a national birth cohort" 171 : 960-968, 2014

73 Dai N, "Different serum protein factor levels in first-episode drug-naive patients with schizophrenia characterized by positive and negative symptoms" 74 : 472-479, 2020

74 Nettleton JA, "Dietary patterns are associated with biochemical markers of inflammation and endothelial activation in the Multi-Ethnic Study of Atherosclerosis (MESA)" 83 : 1369-1379, 2006

75 Wardenaar KJ, "Diagnostic heterogeneity in psychiatry: towards an empirical solution" 11 : 201-, 2013

76 American Psychiatric Association, "Diagnostic and statistical manual of mental disorders" American Psychiatric Association 2013

77 Gattaz WF, "Decreased S100-beta protein in schizophrenia: preliminary evidence" 43 : 91-95, 2000

78 Morera-Fumero AL, "Day/night changes in serum S100B protein concentrations in acute paranoid schizophrenia" 75 : 207-212, 2017

79 Zindel J, "DAMPs, PAMPs, and LAMPs in immunity and sterile inflammation" 15 : 493-518, 2020

80 Xiong P, "Combining serum protein concentrations to diagnose schizophrenia: a preliminary exploration" 75 : e794-e801, 2014

81 Chen S, "Cognitive dysfunction correlates with elevated serum S100B concentration in drugfree acutely relapsed patients with schizophrenia" 247 : 6-11, 2017

82 Lee J, "Cigarette smoking and inflammation: cellular and molecular mechanisms" 91 : 142-149, 2012

83 Mousa RF, "Chronic fatigue syndrome and fibromyalgia-like symptoms are an integral component of the phenome of schizophrenia: neuro-immune and opioid system correlates" 36 : 169-183, 2021

84 Zhang XY, "Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia" 65 : 940-947, 2004

85 Song X, "Changes in pro-inflammatory cytokines and body weight during 6-month risperidone treatment in drug naïve, first-episode schizophrenia" 231 : 319-325, 2014

86 Donato R, "Calcium-independent, pH-regulated effects of S-100 proteins on assembly-disassembly of brain microtubule protein in vitro" 263 : 106-110, 1988

87 Egger M, "Bias in meta-analysis detected by a simple, graphical test" 315 : 629-634, 1997

88 Eaton WW, "Association of schizophrenia and autoimmune diseases: linkage of Danish national registers" 163 : 521-528, 2006

89 Khandaker GM, "Association between circulating levels of C-reactive protein and positive and negative symptoms of psychosis in adolescents in a general population birth cohort" 143 : 534-542, 2021

90 Tourjman V, "Antipsychotics’ effects on blood levels of cytokines in schizophrenia: a meta-analysis" 151 : 43-47, 2013

91 Barker V, "An integrated biopsychosocial model of childhood maltreatment and psychosis" 206 : 177-180, 2015

92 Land W, "Allograft injury mediated by reactive oxygen species: from conserved proteins of Drosophila to acute and chronic rejection of human transplants. Part II: role of reactive oxygen species in the induction of the heat shock response as a regulator of innate" 17 : 31-44, 2003

93 Kozłowska E, "Alarmins (IL-33, sST2, HMGB1, and S100B) as potential biomarkers for schizophrenia" 138 : 380-387, 2021

94 Capuzzi E, "Acute variations of cytokine levels after antipsychotic treatment in drug-naïve subjects with a first-episode psychosis: a meta-analysis" 77 : 122-128, 2017

95 Saha S, "A systematic review of mortality in schizophrenia:is the differential mortality gap worsening over time?" 64 : 1123-1131, 2007

96 Duval S, "A nonparametric “trim and fill” method of accounting for publication bias in meta-analysis" 95 : 89-98, 2000

97 Iager AC, "A negative symptom rating scale" 16 : 27-36, 1985

98 Orwin RG, "A fail-safe N for effect size in meta-analysis" 8 : 157-159, 1983